Sections

Navigation

Media Hero

Landing Hero

Inobrodib

A first-in-class oral anti-cancer drug

Inobrodib is a small molecule inhibitor, taken orally as a simple capsule. It inhibits p300 and CBP through binding into the conserved bromodomain of the twin proteins. This impacts the expression of key cancer drivers including MYC, IRF4 and the androgen receptor (AR) and its variants.

Statistic Set

50+

Epigenetic-related targets

investigated over time by the CellCentric team

1

Drug prioritised, advanced

investigated over time by the CellCentric team

30

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Text Centred

Lorem ipsum

Inobrodib is a first-in-class clinical inhibitor of p300/CBP and is being applied to treat a number of specific cancer types that are currently under addressed:

WYSIWYG

Stand first — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod temp incididunt ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tortor at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharetra sit amet aliquam.

Paragraph 1 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharet sit amet aliquam. Auctor neque vitae tempus quam pellentesque nec nam aliquam sem. Proin nibh nis condimentum id venenatis a condimentum vitae sapien.

Paragraph 2 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharet sit amet aliquam.

Paragraph 3 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in.

Twitter Feed

Latest tweets from @Cellcentric

Press Release Card Set

Icon Card Set

FDC40D06-9F76-4E8A-AF33-68251D6B17C1

Haematological cancers

Relapsed/refractory haematological cancers including Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma(NHL) and Myelodysplastic Syndromes (MDS)

70F65CDB-84D7-4DBF-B9A3-94D23EB86997

Prostate
Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC). Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt

EE166FAB-75DE-42DE-AA96-2E0B25D58CCA

Targeted Tumours

inobrodib can potentially target tumours with amplified expression of certain tumour driving proteins that are regulated by p300/CBP.

Image Split Left

The science behind inobrodib

Inobrodib was developed by CellCentric from initial hits through to an optimised compound and onto a clinical candidate. The compound has been evaluated extensively non-clinically, demonstrating its impact on p300/CBP inhibition in vivo.

Targeting the bromodomain of p300 and CBP

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ac tortor vitae purus faucibus ornare. Viverra justo nec ultrices dui sapien eget. Metus aliquam eleifend mi in nulla posuere sollicitudin aliquam. Nisi est sit amet facilisis magna etiam tempor.

A differentiated and highly selective inhibitor

Mi ipsum faucibus vitae aliquet nec ullamcorper. Turpis egestas sed tempus urna et pharetra pharetra massa. Metus dictum at tempor commodo. Porttitor leo a diam sollicitudin tempor id eu nisl. Habitant morbi tristique senectus et netus et malesuada fames. Ullamcorper a lacus vestibulum sed arcu.

Image Split Right

Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ac tortor vitae purus faucibus ornare. Viverra justo nec ultrices dui sapien eget. Metus aliquam eleifend mi in nulla posuere sollicitudin aliquam. Nisi est sit amet facilisis magna etiam tempor.

The science behind inobrodib

Inobrodib was developed by CellCentric from initial hits through to an optimised compound and onto a clinical candidate.
The compound has been evaluated extensively non-clinically, demonstrating its impact on p300/CBP inhibition in vivo.

Latest publications

Scientific publications, Posters and Presentations

View and download posters from recent key conferences

CTA Cards

Clinical trials

Developing inobrodib to transform cancer treatment

Inobrodib

A first-in-class oral anti-cancer drug

Graphic CTA

Clinical trials

Developing inobrodib to transform cancer treatment

Image CTA

News

Stay up to date with our news and press releases

Footer